Literature DB >> 29486303

Effect of storage temperature on the stability of spray dried bacteriophage powders.

Sharon S Y Leung1, Thaigarajan Parumasivam2, An Nguyen1, Thomas Gengenbach3, Elizabeth A Carter4, Nicholas B Carrigy5, Hui Wang5, Reinhard Vehring5, Warren H Finlay5, Sandra Morales6, Warwick J Britton7, Elizabeth Kutter8, Hak-Kim Chan9.   

Abstract

This study aimed to assess the robustness of using a spray drying approach and formulation design in producing inhalable phage powders. Two types of Pseudomonas phages, PEV2 (Podovirus) and PEV40 (Myovirus) in two formulations containing different amounts of trehalose (70% and 60%) and leucine (30% and 40%) were studied. Most of the surface of the produced powders was found to be covered in crystalline leucine. The powders were stored at 4 °C and 20 °C under vacuum. The phage stability and in vitro aerosol performance of the phage powders were examined on the day of production and after 1, 3 and 12 months of storage. A minor titer loss during production was observed for both phages (0.2-0.8 log10 pfu/ml). The storage stability of the produced phage powders was found to be phage and formulation dependent. No further reduction in titer occurred for PEV2 powders stored at 4 °C across the study. The formulation containing 30% leucine maintained the viability of PEV2 at 20 °C, while the formulation containing 40% leucine gradually lost titer over time with a storage reduction of ∼0.9 log10 pfu/ml measured after 12 months. In comparison, the PEV40 phage powders generally had a ∼ 0.5 log10 pfu/ml loss upon storage regardless of temperature. When aerosolized, the total in vitro lung doses of PEV2 were of the order of 107 pfu, except the formulation containing 40% leucine stored at 20 °C which had a lower lung dose. The PEV40 powders also had lung doses of 106-107 pfu. The results demonstrate that spray dried Myoviridae and Podoviridae phage in a simple formulation of leucine and trehalose can be successfully stored for one year at 4 °C and 20 °C with vacuum packaging.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; PEV2; PEV40; Phage; Phage dry powder; Pulmonary infections

Mesh:

Substances:

Year:  2018        PMID: 29486303      PMCID: PMC5948144          DOI: 10.1016/j.ejpb.2018.02.033

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  26 in total

1.  In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis.

Authors:  L Golshahi; K H Lynch; J J Dennis; W H Finlay
Journal:  J Appl Microbiol       Date:  2010-09-28       Impact factor: 3.772

2.  Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection.

Authors:  Lisa A Carmody; Jason J Gill; Elizabeth J Summer; Uma S Sajjan; Carlos F Gonzalez; Ryland F Young; John J LiPuma
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

Review 3.  Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.

Authors:  Elizabeth M Ryan; Sean P Gorman; Ryan F Donnelly; Brendan F Gilmore
Journal:  J Pharm Pharmacol       Date:  2011-07-06       Impact factor: 3.765

4.  Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections.

Authors:  Sharon S Y Leung; Thaigarajan Parumasivam; Fiona G Gao; Nicholas B Carrigy; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan
Journal:  Pharm Res       Date:  2016-02-29       Impact factor: 4.200

5.  Effectiveness of bacteriophages in the sputum of cystic fibrosis patients.

Authors:  E Saussereau; I Vachier; R Chiron; B Godbert; I Sermet; N Dufour; J-P Pirnay; D De Vos; F Carrié; N Molinari; L Debarbieux
Journal:  Clin Microbiol Infect       Date:  2014-07-26       Impact factor: 8.067

6.  Development of formulations that enhance physical stability of viral vectors for gene therapy.

Authors:  M A Croyle; X Cheng; J M Wilson
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

7.  Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections.

Authors:  Laurent Debarbieux; Dominique Leduc; Damien Maura; Eric Morello; Alexis Criscuolo; Olivier Grossi; Viviane Balloy; Lhousseine Touqui
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

8.  Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler.

Authors:  Nicholas B Carrigy; Rachel Y Chang; Sharon S Y Leung; Melissa Harrison; Zaritza Petrova; Welkin H Pope; Graham F Hatfull; Warwick J Britton; Hak-Kim Chan; Dominic Sauvageau; Warren H Finlay; Reinhard Vehring
Journal:  Pharm Res       Date:  2017-06-23       Impact factor: 4.200

9.  Decreasing Enterobacter sakazakii (Cronobacter spp.) food contamination level with bacteriophages: prospects and problems.

Authors:  Sophie Zuber; Catherine Boissin-Delaporte; Lise Michot; Carol Iversen; Benjamin Diep; Harald Brüssow; Pieter Breeuwer
Journal:  Microb Biotechnol       Date:  2008-11       Impact factor: 5.813

10.  Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization).

Authors:  Maia Merabishvili; Chris Vervaet; Jean-Paul Pirnay; Daniel De Vos; Gilbert Verbeken; Jan Mast; Nino Chanishvili; Mario Vaneechoutte
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more
  16 in total

1.  Storage stability of inhalable phage powders containing lactose at ambient conditions.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Elizabeth Kutter; Sandra Morales; Warwick Britton; Jian Li; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2019-01-31       Impact factor: 5.875

Review 2.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

3.  Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2019-08-06       Impact factor: 5.571

4.  Microencapsulation of phages to analyze their demeanor in physiological conditions.

Authors:  Esra Acar Soykut; Emine Kübra Tayyarcan; Şefika Evran; İsmail Hakkı Boyacı; İbrahim Çakır; Maha Khaaladi; Sami Fattouch
Journal:  Folia Microbiol (Praha)       Date:  2019-02-12       Impact factor: 2.099

Review 5.  Physical stability of dry powder inhaler formulations.

Authors:  Nivedita Shetty; David Cipolla; Heejun Park; Qi Tony Zhou
Journal:  Expert Opin Drug Deliv       Date:  2019-12-13       Impact factor: 6.648

Review 6.  Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory.

Authors:  Katherine M Caflisch; Robin Patel
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

Review 7.  Inhaled Delivery of Anti-Pseudomonal Phages to Tackle Respiratory Infections Caused by Superbugs.

Authors:  Hak-Kim Chan; Rachel Yoon Kyung Chang
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2021-12-30       Impact factor: 3.440

8.  Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29.

Authors:  Nicholas B Carrigy; Sasha E Larsen; Valerie Reese; Tiffany Pecor; Melissa Harrison; Philip J Kuehl; Graham F Hatfull; Dominic Sauvageau; Susan L Baldwin; Warren H Finlay; Rhea N Coler; Reinhard Vehring
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

9.  Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate.

Authors:  Mellissa Gomez; Joseph McCollum; Hui Wang; Mani Ordoubadi; Chester Jar; Nicholas B Carrigy; David Barona; Isobel Tetreau; Michelle Archer; Alana Gerhardt; Chris Press; Christopher B Fox; Ryan M Kramer; Reinhard Vehring
Journal:  Int J Pharm       Date:  2020-12-02       Impact factor: 5.875

10.  Evaluation of the Stability of Bacteriophages in Different Solutions Suitable for the Production of Magistral Preparations in Belgium.

Authors:  Hans Duyvejonck; Maya Merabishvili; Mario Vaneechoutte; Steven de Soir; Rosanna Wright; Ville-Petri Friman; Gilbert Verbeken; Daniel De Vos; Jean-Paul Pirnay; Els Van Mechelen; Stefan J T Vermeulen
Journal:  Viruses       Date:  2021-05-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.